Ozempic, Wegovy & Mounjaro: Thyroid Cancer Risk – Latest Findings Explained
- Public concern regarding a potential link between GLP-1 receptor agonist medications – including Ozempic®, Wegovy® and Mounjaro® – and thyroid cancer has been addressed in a newly released...
- The increasing use of these medications for both diabetes management and weight loss has understandably prompted questions about potential health risks.
- “Thyroid cancer is not a single disease, and that distinction matters,” explained Dr.
Public concern regarding a potential link between GLP-1 receptor agonist medications – including Ozempic®, Wegovy® and Mounjaro® – and thyroid cancer has been addressed in a newly released white paper from the Clayman Thyroid Center. The comprehensive review, published on , concludes that the available human data do not demonstrate these medications cause or affect the most common types of thyroid cancer.
The increasing use of these medications for both diabetes management and weight loss has understandably prompted questions about potential health risks. The white paper, titled “Do GLP-1 Weight-Loss Shots Like Ozempic and Mounjaro Really Raise Thyroid Cancer Risk? The Latest Facts Explained,” examined mechanistic research, clinical trials, large population studies, and real-world clinical experience to arrive at its conclusions.
“Thyroid cancer is not a single disease, and that distinction matters,” explained Dr. Gary L. Clayman, FACS, FACE, senior author of the white paper and a high-volume thyroid cancer surgeon. He emphasized that the Food and Drug Administration (FDA) boxed warning associated with GLP-1 medications specifically pertains to a rare form of the disease, medullary thyroid carcinoma, and does not apply to the more prevalent types of thyroid cancer, which account for over 95% of cases.
The FDA’s initial warning stemmed from studies conducted on rodents, where exposure to GLP-1 drugs led to the development of C-cell tumors. However, significant biological differences exist between rodents and humans, and extensive human studies have not replicated this pattern. According to the Clayman Thyroid Center’s review, major international cohort studies and meta-analyses have not found increased rates of thyroid cancer among individuals using GLP-1 medications.
The review also points to the possibility of detection bias as a contributing factor in some studies that have suggested a potential association. Patients undergoing GLP-1 therapy often receive more frequent medical care, including imaging and specialist consultations, which can increase the likelihood of identifying pre-existing thyroid nodules or small cancers that might otherwise go unnoticed. “When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there,” said Dr. Rashmi Roy, FACS, co-author of the white paper. “That is very different from a drug actually causing a new cancer.”
The white paper specifically addresses the common types of thyroid cancer – papillary, follicular, and Hürthle cell – and states that current evidence does not support the idea that GLP-1 medications cause these diseases or worsen their course. For patients with these types of thyroid cancer, decisions regarding GLP-1 therapy should be individualized, taking into account the potential metabolic benefits and overall health goals.
However, the authors stress the importance of caution for a specific subset of patients. GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or those with Multiple Endocrine Neoplasia type 2 (MEN2), consistent with existing FDA labeling.
The Clayman Thyroid Center, which treats approximately 2,000 thyroid cancer patients annually, has not observed a surge in cases of medullary thyroid carcinoma linked to GLP-1 medication use within its large clinical practice. “In a practice that sees more thyroid cancer than almost anywhere globally, we are not seeing a surge of medullary thyroid cancer linked to these medications,” Dr. Clayman stated.
The authors also caution against the potential for misinterpretation of headlines and social media summaries, which can oversimplify the nuances between different cancer subtypes and exaggerate perceived risks. Such confusion could lead patients to discontinue beneficial medications or experience unnecessary anxiety.
“Patients deserve clear, evidence-based guidance,” Dr. Roy said. “Our goal is to provide clarity so people can make informed decisions with their physicians.”
The full white paper is available on the Clayman Thyroid Center’s website and is intended as a resource for clinicians, patients, and the media navigating this complex topic.
The Clayman Thyroid Center, founded by a leading thyroid surgeon, is the highest-volume thyroid cancer referral center in the United States, offering personalized care and a wide range of surgical options.